



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## Journal Pre-proof

Long Covid: does it exist? What is it? We can we do for sufferers?

Edward P Hoffer MD, FACP, FACC, FACMI

PII: S0002-9343(21)00399-5

DOI: <https://doi.org/10.1016/j.amjmed.2021.05.023>

Reference: AJM 16338



To appear in: *The American Journal of Medicine*

Please cite this article as: Edward P Hoffer MD, FACP, FACC, FACMI , Long Covid: does it exist? What is it? We can we do for sufferers?, *The American Journal of Medicine* (2021), doi: <https://doi.org/10.1016/j.amjmed.2021.05.023>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc.

Long Covid: does it exist? What is it? We can we do for sufferers?

Commentary

Edward P Hoffer MD, FACP, FACC, FACMI

Associate Professor of Medicine, part-time, Harvard

50 Staniford Street, Suite 750

Boston, MA 02114

ehoffer@mgh.harvard.edu or ehoffer@gmail.com

Funding: none

Conflict of interest: none

Key words: Covid-19, Long Covid

Running title: Long Covid: what is it?

As we gradually work our way out of the Covid-19 pandemic in the United States thanks to vaccinations, we will hopefully see many fewer desperately ill patients on ventilators and fewer deaths. Looming over the profession is the large and growing numbers of people with what has been termed “long Covid:” patients who have recovered from their acute illness who present with many persistent complaints. There is still considerable confusion about this entity. There is vigorous debate over whether this is a “real” entity with a biologic basis or whether it is psychosomatic. The NIH has announced plans to support research into long Covid, but patients are presenting to their physicians now and seeking help.

There are two relatively distinct forms that “long Covid” can take: persisting symptoms in those who were seriously ill and new symptoms in those, often younger people, who had only mild or even no symptoms with their acute infection.

It is not surprising that very sick Covid-19 survivors have symptoms that persist long after they are discharged from hospital. In recent years increased attention has been paid to the Post-ICU

syndrome (1,2). A prolonged ICU stay is often followed by persistent cognitive dysfunction, muscle weakness and intrusive memories similar to those seen with post-traumatic stress disorder.

Hospitalized Covid-19 patients with critical or severe illness were studied at discharge. 77% were below the 2.5<sup>th</sup> percentile in functional capacity assessed by the one-minute sit-to-stand test and 15 of 48 had oxygen desaturation. After three months only one patient had a result above the 50th percentile (3). Swedish investigators found that more than half of ICU-treated Covid-19 survivors had impaired CO diffusing capacity at four months post discharge (4). In France, 478 patients discharged from hospital were interviewed by telephone at four months after discharge. 51% reported at least one symptom that had not existed before their illness. The most common were fatigue in 31%, cognitive impairment in 21% and dyspnea in 16%. Lung CT was done in 171 patients and 63% had abnormalities, mostly subtle ground-glass opacities. In Italy, 143 previously hospitalized patients were assessed at a mean of 60.3 days after onset of symptoms. Only 18 (12.6%) were asymptomatic. The most commonly reported symptoms were fatigue (53%), dyspnea (43.4%), joint pain (27.3%) and chest pain (21.7%) (6).

These patients can often be assured that their symptoms should improve with time and seem to be helped by an active rehab program (3).

Much more challenging are the patients whose initial infection was mild or even asymptomatic. Swedish investigators compared a group of health care professionals who were seropositive for SARS-CoV-2 at enrollment and who reported no or mild antecedent symptoms with seronegative patients at eight months after testing (7). Most symptoms were mild, but 26% of seropositive subjects reported at least one moderate to severe symptom for at least 2 months compared to 9% of seronegative subjects. Mexican investigators studied 115 patients with mostly mild to moderate PCR-confirmed Covid-19 at least 30 days after symptom onset. Four were sick enough to require ICU care. There was a severe decrease in quality of life in 56% (8).

The University of Washington followed 177 patients with documented Covid-19, of whom 16 were admitted to hospital and 150 were treated as outpatients; 64% of the latter group sought no care after diagnosis. Of the outpatients contacted a mean of 169 days after symptom onset, 31% had one or more persisting symptoms (9).

Patients' symptoms after mild Covid-19 include anosmia, fatigue, palpitations, insomnia, hyperhidrosis, dysgeusia, "brain fog" and dyspnea (6-10).

It is easy for physicians to attribute symptoms to anxiety, but this is neither helpful to our patients nor necessarily true. "Hard" neurologic illnesses, including ischemic strokes and intracranial hemorrhage have been found to be more common in patients recovered from even mild Covid-19 (11). Certainly the two leading hypotheses as to the cause of "long-Covid" are psychosomatic and immune-mediated, but persisting small vessel thrombi have also been postulated.

Pending the results of larger controlled studies, what can we offer our patients? While anecdotal at this point, many patients with persisting symptoms after a mild/asymptomatic infection have reported improvement in symptoms after vaccination. Since these patients are still at risk for reinfection, advising vaccination is appropriate whether or not it helps their symptoms. Critically, we should not dismiss their complaints as being “all in their head.” This may be wrong, and even if correct is not helpful. It is appropriate to acknowledge their distress, get those with fatigue and/or dyspnea in a structured exercise program, and work with all on symptomatic relief.

#### References:

1. Myers EA, Smith DA, Allen SR, Kaplan LJ. *Post-ICU syndrome: Rescuing the undiagnosed*. JAAPA 2016 Apr;29(4):34-7
2. Svenningsen H, Langhorn L, Agard AS, Dreyer P. *Post-ICU symptoms, consequences and follow-up: an integrative review*. Nurs Crit Care 2017 Jul;22(4):212-220
3. Martin I, Braem F, Baudet L et al. *Follow-up of functional exercise capacity in patients with Covid-19: it is improved by telerehabilitation*. Resp Med 2021 epub ahead of print. <https://doi.org/10.1016/j.rmed.2021.106438>
4. Ekblom E, Frithiof R, Emilsson OI et al. *Impaired diffusing capacity for carbon monoxide is common in critically ill Covid-19 patients at four months post-discharge*. Resp Med 2021 epub ahead of print. <https://doi.org/10.1016/j.rmed.2021.106394>
5. The Writing Committee for the COMEBAC Study Group. *Four-month clinical status of a cohort of patients after hospitalization for Covid-19*. JAMA 2021;325(15):1525-1534
6. Carfi A, Bernabei R, Landi F et al. *Persistent symptoms in patients after acute Covid-19*. JAMA 2020;324(6):603-605
7. Havervall S, Rosell A, Phillipson M et al. *Symptoms and functional impairment assess 8 months after mild Covid-19 among health care workers*. JAMA 2021 Apr 7;e215612. doi: 10.1001/jama.2021.5612. Online ahead of print
8. Ordinola Navarro AO, Cervantes-Bojalil J, Quevedo O de J C et al. *Decreased quality of life and spirometric alterations even after mild-moderate Covid-19*. Respir Med. 2021 Apr 14;181:106391. doi: 10.1016/j.rmed.2021.106391. Online ahead of print.
9. Logue JK, Franko NM, McCulloch DJ et al. *Sequelae in adults at 6 months after Covid-19 infection*. JAMA Network Open 2021;4(2):e210830
10. Huang Y, Pinto MD, Borelli JL et al. *COVID symptoms, symptom clusters and predictors for becoming a long-hauler*. medRxiv. 2021 Mar 5:2021.03.03.21252086. doi: 10.1101/2021.03.03.21252086. Preprint
11. Taquet M, Geddes JR, Husain M et al. *6-month neurologic and psychiatric outcomes in 236,379 survivors of Covid-19: a retrospective cohort study using electronic health records*. Lancet Psychiatry 2021 May;8(5):416-427